Sangamo Therapeutics (NASDAQ: SGMO) is a clinical-stage genomic medicine company that develops gene therapy and genetic engineering technologies. Revenue comes from collaboration agreements with pharmaceutical partners, including upfront license fees, research service reimbursements, and milestone payments tied to development and commercial events. In FY2025, the company recorded $37.1 million in revenue from collaboration agreements (year ended December 31, 2025). Key licensing partners include Genentech (a member of the Roche Group), Astellas Gene Therapies, and Eli Lilly and Company, all of whom entered license agreements for Sangamo's STAC-BBB technology in 2025. The company has historically operated at a loss and has not generated product revenue from commercialized medicines. Alexander D. MacRae serves as President and Chief Executive Officer, as of the 10-K filing dated March 30, 2026. The company recorded a $13.2 million impairment of long-lived assets during FY2025, including charges related to its Brisbane facility.

Revenue model

Collaboration agreement revenue: upfront license fees, research and development service reimbursements, milestone payments (preclinical, clinical, regulatory, and sales-based), and royalties on future commercialized products. FY2025 collaboration revenue: $37.1 million (year ended December 31, 2025). No commercial product revenue disclosed in the filing excerpts.

Products and services

STAC-BBB technology licensed to Genentech, Astellas Gene Therapies, and Eli Lilly and Company (license agreements entered in 2025). Gene therapy and genetic engineering platform technologies. Research and development services provided to collaboration partners.

Customers and end markets

Pharmaceutical and biotechnology company partners as primary customers. Named partners as of FY2025: Genentech (Roche Group), Astellas Gene Therapies, Eli Lilly and Company. End markets: gene therapy, rare disease, and potentially CNS/neurological indications implied by STAC-BBB licensing activity.

Value-chain role

IP licensor and research-stage drug developer. Licenses genomic medicine platform technology and provides R&D services to large pharmaceutical partners. Relies on contract manufacturing organizations (CMOs) for manufacturing.

Geographic exposure

Operations referenced at a Brisbane facility. Collaboration partners are multinational pharmaceutical companies. No specific geographic revenue breakdown supported by the filing excerpts.

Source: SEC 10-K, filed 2026-03-30

Industry: Biological Products, (No Diagnostic Substances) Peers: Kalaris Therapeutics Inc Arcellx Inc Coherus Oncology Inc MannKind Corp Mirum Pharmaceuticals Inc Northwest Biotherapeutics Inc Viridian Therapeutics Inc Replimune Group Inc Seres Therapeutics Inc